C4 therapeutics reports second quarter 2024 financial results and recent business highlights

Preliminary monotherapy data from the ongoing cft1946 phase 1 trial in braf v600x solid tumors to be presented at esmo congress 2024; initiated monotherapy expansion cohort in melanoma and combination cohort with cetuximab in colorectal cancer

CCCC Ratings Summary

CCCC Quant Ranking